10,11-dihydro-10,11-epoxy-5H-dibenzocycloheptene | 16145-11-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 二苯并环庚烯
• 英文名称: 10,11-dihydro-10,11-epoxy-5H-dibenzocycloheptene
• 英文别名: 1a,10b-dihydro-6H-dibenzo[3,4:6,7]cyclohept[1,2-b]oxirene；3-oxatetracyclo[10.4.0.02,4.05,10]hexadeca-1(16),5,7,9,12,14-hexaene
• CAS: 16145-11-2
• 化学式: C₁₅H₁₂O
• 分子量: 208.26
• InChiKey: IIEKDDXXPDUGRD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2932999099

反应信息

• 作为反应物：
  描述：

  10,11-dihydro-10,11-epoxy-5H-dibenzocycloheptene 以25%的产率得到
  参考文献：
  名称：

  BELLUCCI, G.;BERTI, G.;CHIAPPE, C.;FABRI, F.;MARIONI, F., J. ORG. CHEM., 54,(1989) N, C. 968-970

  摘要：

  DOI：
• 作为产物：
  描述：

  5H-二苯并[a,d]环庚烯 在 间氯过氧苯甲酸 作用下， 以 氯仿 为溶剂， 反应 8.0h， 以80%的产率得到10,11-dihydro-10,11-epoxy-5H-dibenzocycloheptene
  参考文献：
  名称：

  Product enantioselectivity in the microsomal epoxide hydrolase catalyzed hydrolysis of 10,11-dihydro-10,11-epoxy-5H-dibenzo[a,d]cycloheptene

  摘要：

  DOI：

  10.1021/jo00265a044

文献信息

• Reactivity and crystal structure of 10,11 -dihdro-10,11-epoxy-5H-dibenzo[a,d]cycloheptene. A comparison with cis-stilbene oxide
  作者：Giuseppe Bellucci、Cinzia Chiappe、F. Marioni、Riccardo Spagna

  DOI：10.1039/p29900002147

  日期：——

  The kinetics and product distributions for the HClO4 catalysed hydrolysis of 10,11-diydro-10,11-epoxy-5H-dibenzo[a,d]cycloheptene1 and of cis-stilbene oxide 6 in tetrahydrofuran–water (8:2), have been investigated by HPLC. The former epoxide gives 9,10-dihydroanthracene-9-carbaldehyde 4 and the trans- and cis-10,11-dihydro-5H-dibenzo[a,d]cycloheptene-10,11-diols, 2 and 3, in he ratio 6:6:1. cis-Stilbene

  为高氯酸的动力学和产品分布4 10,11- diydro -10,11-环氧-5-催化水解ħ -二苯并[一，d ]环庚烯1，并且顺式-茋氧化物6在四氢呋喃-水（8:2 ），已通过HPLC进行了研究。前者环氧化物使9,10-二氢-9-甲醛4和反式-和顺-10,11-二氢-5- ħ -二苯并[一，d ]环庚烯-10,11-二醇，2和3，在他比例6：6：1。顺式-氧化二苯乙烯与速率常数ca反应。低十倍，得到大部分（±）-1,2-二苯乙烷-1,2-二醇。这些差异可以用1的晶体结构来解释，该晶体结构由于C（10）和C（11）处键角的增大而显示出相当大的环应变。这种结构也为1相对于6的微粒体环氧化物水解酶催化的水合速率低得多提供了一种解释。
• Substituted tetracyclic tetrahydrofuran derivatives
  申请人：Janssen Pharmaceutica, N.V.

  公开号：US06057441A1

  公开（公告）日：2000-05-02

  This invention concerns the compounds of formula (I), ##STR1## the N-oxide forms, the pharmaceutically acceptable addition salts and the stereoisomeric forms thereof, wherein n is zero to 6; p and q are zero to 4; r is zero to 5; R.sup.1 and R.sup.2 each independently are hydrogen; optionally substituted C.sub.1-6 alkyl; C.sub.1-6 alkylcarbonyl; halomethylcarbonyl; or R.sup.1 and R.sup.2 taken together with the nitrogen atom to which they are attached may form a morpholinyl ring or an optionally substituted heterocycle; each R.sup.3 and R.sup.4 independently are halo, cyano, hydroxy, halomethyl, halomethoxy, carboxyl, nitro, amino, mono- or di(C.sub.1-6 alkyl)amino, C.sub.1-6 alkylcarbonylamino, aminosulfonyl, mono- or di(C.sub.1-6 alkyl)aminosulfonyl, C.sub.1-6 alkyl, C.sub.1-6 alkyloxy, C.sub.1-6 alkylcarbonyl, C.sub.1-6 alkyloxycarbonyl; each R.sup.5 independently is C.sub.1-6 alkyl, cyano or halomethyl; X is CR.sup.6 R.sup.7, NR.sup.8, O, S, S(.dbd.O) or S(.dbd.O).sub.2 ; aryl is optionally substituted phenyl; provided that the compound is other than (.+-.)-3,3a,8,12b-tetrahydro-N-methyl-2H-dibenzo[3,4:6,7]-cyclohepta[1,2-b ]-furan-2-methanamine oxalic acid. The compounds of formula (I) may be used as therapeutic agents in the treatment or the prevention of CNS disorders, cardiovascular disorders or gastrointestinal disorders.

  本发明涉及式（I）的化合物，其中n为0至6；p和q为0至4；r为0至5；R1和R2分别独立地为氢；可选取代的C1-6烷基；C1-6烷基羰基；卤甲基羰基；或R1和R2与它们所连接的氮原子一起可以形成吗啡啡环或可选取代的杂环；每个R3和R4独立地为卤素、氰基、羟基、卤甲基、卤甲氧基、羧基、硝基、氨基、单或双（C1-6烷基）氨基、C1-6烷基羰基氨基、氨基磺酰基、单或双（C1-6烷基）氨基磺酰基、C1-6烷基、C1-6烷氧基、C1-6烷基羰基、C1-6烷氧羰基；每个R5独立地为C1-6烷基、氰基或卤甲基；X为CR6R7、NR8、O、S、S（=O）或S（=O）2；芳基为可选取代的苯基；但该化合物不包括(.+-.)-3,3a,8,12b-四氢-N-甲基-2H-二苯并[3,4:6,7]-环庚[1,2-b]-呋喃-2-甲胺草酸盐。式（I）的化合物可用作治疗中枢神经系统疾病、心血管疾病或胃肠道疾病的治疗剂或预防剂。
• Novel Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain
  申请人：Cid-Nunez Jose Maria

  公开号：US20080262076A1

  公开（公告）日：2008-10-23

  This invention concerns novel substituted tetracyclic tetrahydrofuran derivatives containing a cyclic amine side chain with binding affinities towards dopamine receptors, in particular dopamine D 2 receptors, towards serotonin receptors, in particular 5-HT 2A and 5-HT 2C receptors, and pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production. The compounds according to the invention can be represented by general Formula (I) and comprises also a pharmaceutically acceptable acid or base addition salt thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein all substituents are defined as in Claim 1.

  本发明涉及一种新型取代四环四氢呋喃衍生物，其含有一个环状胺侧链，具有结合多巴胺受体的亲和力，特别是多巴胺D2受体，对5-HT2A和5-HT2C受体的亲和力，以及包含根据本发明的化合物的制药组合物，其用作药物，特别是用于预防和/或治疗一系列精神和神经疾病，特别是某些精神病、心血管和胃动力紊乱，并提供其生产过程。根据本发明的化合物可以用一般式（I）表示，并包括其药学上可接受的酸或碱盐、N-氧化物形式或季铵盐，其中所有取代基在权利要求书1中定义。
• Method of using substituted tetracyclic tetrahydrofuran derivatives
  申请人：Janssen Pharmaceutica N.V.

  公开号：US06194405B1

  公开（公告）日：2001-02-27

  This invention concerns the compounds of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts and the stereoisomeric forms thereof, wherein n is zero to 6; p and q are zero to 4; r is zero to 5; R1 and R2 each independently are hydrogen; optionally substituted C1-6alkyl; C1-6alkylcarbonyl; halomethylcarbonyl; or R1 and R2 taken together with the nitrogen atom to which they are attached may form a morpholinyl ring or an optionally substituted heterocycle; each R3 and R4 independently are halo, cyano, hydroxy, halomethyl, halomethoxy, carboxyl, nitro, amino, mono- or di(C1-6alkyl)amino, C1-6alkylcarbonylamino, aminosulfonyl, mono- or di(C1-6alkyl)aminosulfonyl, C1-6alkyl, C1-6alkyloxy, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl; each R5 independently is C1-6alkyl, cyano or halomethyl; X is CR6R7, NR8, O, S, S(═O) or S(═O)2; aryl is optionally substituted phenyl; provided that the compound is other than (±)-3,3a,8,12b-tetrahydro-N-methyl-2H-dibenzo[3,4:6,7]-cyclohepta[1,2-b]-furan-2-methanamine oxalic acid. The compounds of formula (I) may be used as therapeutic agents in the treatment or the prevention of CNS disorders, cardiovascular disorders or gastrointestinal disorders.

  本发明涉及公式（I）的化合物，其N-氧化物形式，药学上可接受的加合盐和其立体异构体形式，其中n为0至6；p和q为0至4；r为0至5；R1和R2各自独立地为氢；可选取代的C1-6烷基；C1-6烷基羰基；卤甲基羰基；或R1和R2与它们连接的氮原子一起可以形成吗啡啶环或可选取代的杂环；每个R3和R4独立地为卤素，氰基，羟基，卤甲基，卤甲氧基，羧基，硝基，氨基，单或双（C1-6烷基）氨基，C1-6烷基羰基氨基，氨基磺酰基，单或双（C1-6烷基）氨基磺酰基，C1-6烷基，C1-6烷氧基，C1-6烷基羰基，C1-6烷氧羰基；每个R5独立地为C1-6烷基，氰基或卤甲基；X为CR6R7，NR8，O，S，S（═O）或S（═O）2；芳基为可选取代的苯基；但化合物不包括（±）-3,3a,8,12b-四氢-N-甲基-2H-二苯并[3,4:6,7]-环庚[1,2-b]-呋喃-2-甲胺草酸盐。公式（I）的化合物可用作治疗或预防中枢神经系统疾病，心血管疾病或胃肠道疾病的治疗剂。
• Bellucci, Giuseppe; Chiappe, Cinzia; Marioni, Franco, Gazzetta Chimica Italiana, 1993, vol. 123, # 2, p. 87 - 91
  作者：Bellucci, Giuseppe、Chiappe, Cinzia、Marioni, Franco、Cabiddu, Maria Grazia、Cabiddu, Salvatore

  DOI：——

  日期：——